# Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors

> **NCT04864379** · PHASE1 · UNKNOWN · sponsor: **Sir Run Run Shaw Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **BIOLOGICAL:** iNeo-Vac-P01
- **OTHER:** GM-CSF
- **DRUG:** PD-1
- **PROCEDURE:** RFA

## Key facts

- **NCT ID:** NCT04864379
- **Lead sponsor:** Sir Run Run Shaw Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-03
- **Primary completion:** 2025-08-03
- **Final completion:** 2025-08-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04864379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04864379, "Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04864379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*